← Back to headlines
Aurinia Pharmaceuticals Targets $305M–$315M LUPKYNIS Sales for 2026
Aurinia Pharmaceuticals aims for LUPKYNIS sales between $305 million and $315 million in 2026, as it continues to advance the clinical development of aritinercept.
26 Feb, 20:28 — 26 Feb, 20:28
ℹOnly 1 source covers this story
